Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
Abstract Background Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adj...
Main Authors: | Ann Livingstone, Kathy Dempsey, Martin R. Stockler, Kirsten Howard, Georgina V. Long, Matteo S. Carlino, Alexander M. Menzies, Rachael L. Morton |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08752-1 |
Similar Items
-
Risk of diabetes mellitus in physicians: a nationwide study in Taiwan
by: Shang-Gyu Lee, et al.
Published: (2019-08-01) -
Physician-performed Focused Ultrasound: An Update on Its Role and Performance
by: Sornsupha Limchareon, et al.
Published: (2015-06-01) -
DIAGNOSIS 3 : MORTUARI /
by: Fahd Razy, author, et al.
Published: (2016) -
The Clinician Investigator Program at the University of Ottawa
by: Jonathan Angel
Published: (2014-05-01) -
Physician preference items: what factors matter to surgeons? Does the vendor matter?
by: Burns LR, et al.
Published: (2018-01-01)